A new study reveals that age-related mutations in blood stem cells — a process called clonal hematopoiesis — may drive aortic aneurysm growth by turning immune cells into bone-dissolving-like cells that weaken artery walls. Researchers found this destructive process is controlled by the RANK/RANKL pathway, the same signaling system targeted by osteoporosis drugs. When scientists blocked this pathway in animal models, aneurysm growth slowed significantly. Even more promising, existing FDA-approved drugs like alendronate and anti-RANKL antibodies produced similar results. Around 60% of aneurysm surgery patients in the study carried these blood mutations, and they showed faster aneurysm progression. This points toward a potential drug-based treatment for a condition that currently has no approved medications to slow its progression.
